Characteristics of 306 Children With Newly Diagnosed ALL Treated According to DCLSG Protocols VII or VIII, Divided in Patients of Whom We Did (n = 190) or Did Not (n = 116) Receive Material for In Vitro Cellular Drug-Resistance Testing
| . | Material Received . | Material Not Received . | P Value . |
|---|---|---|---|
| No. of patients | 190 | 116 | |
| Age in mo, median (range) | 58 (2-190) | 49 (1-215) | .13 |
| Female/male ratio | 79:111 | 60:56 | .08 |
| WBC × 109/L, median (range) | 19.5 (0.5-746) | 6.5 (0.3-481) | <.0001 |
| BFM risk factor,* median (range) | 0.99 (0-2.05) | 0.78 (0-1.97) | <.0001 |
| FAB type | .07 | ||
| L1 | 155 | 102 | |
| L2 | 33 | 12 | |
| AUL† | 2 | 0 | |
| Unknown | 0 | 2 | |
| Immunophenotype | .002 | ||
| Pro-B | 9 | 4 | |
| Common | 99 | 70 | |
| Pre-B | 45 | 25 | |
| T | 36 | 9 | |
| Unknown | 1 | 8 | |
| DNA ploidy | .34‡ | ||
| Nonhyperdiploid | 137 | 40 | |
| Hyperdiploid | 34 | 14 | |
| Unknown | 19 | 62 | |
| DCLSG protocol VII/VIII | 100/90 | 62/54 | .89 |
| Risk group | <.001 | ||
| Low | 54 | 58 | |
| Medium | 115 | 53 | |
| High | 21 | 5 | |
| Follow-up, median (range) (in mo) | 47 (17-81) | 51 (31-77) | .32 |
| Events | .09 | ||
| No CR | 1 | 1 | |
| Relapse | 49 | 20 | |
| Early death | 2 | 0 | |
| Toxic death | 4 | 3 | |
| No event | 134 | 92 | |
| pDFS (%) | .05 | ||
| 3 yr (SE) | 76 (4) | 84 (4) | |
| 4 yr (SE) | 71 (5) | 80 (5) |
| . | Material Received . | Material Not Received . | P Value . |
|---|---|---|---|
| No. of patients | 190 | 116 | |
| Age in mo, median (range) | 58 (2-190) | 49 (1-215) | .13 |
| Female/male ratio | 79:111 | 60:56 | .08 |
| WBC × 109/L, median (range) | 19.5 (0.5-746) | 6.5 (0.3-481) | <.0001 |
| BFM risk factor,* median (range) | 0.99 (0-2.05) | 0.78 (0-1.97) | <.0001 |
| FAB type | .07 | ||
| L1 | 155 | 102 | |
| L2 | 33 | 12 | |
| AUL† | 2 | 0 | |
| Unknown | 0 | 2 | |
| Immunophenotype | .002 | ||
| Pro-B | 9 | 4 | |
| Common | 99 | 70 | |
| Pre-B | 45 | 25 | |
| T | 36 | 9 | |
| Unknown | 1 | 8 | |
| DNA ploidy | .34‡ | ||
| Nonhyperdiploid | 137 | 40 | |
| Hyperdiploid | 34 | 14 | |
| Unknown | 19 | 62 | |
| DCLSG protocol VII/VIII | 100/90 | 62/54 | .89 |
| Risk group | <.001 | ||
| Low | 54 | 58 | |
| Medium | 115 | 53 | |
| High | 21 | 5 | |
| Follow-up, median (range) (in mo) | 47 (17-81) | 51 (31-77) | .32 |
| Events | .09 | ||
| No CR | 1 | 1 | |
| Relapse | 49 | 20 | |
| Early death | 2 | 0 | |
| Toxic death | 4 | 3 | |
| No event | 134 | 92 | |
| pDFS (%) | .05 | ||
| 3 yr (SE) | 76 (4) | 84 (4) | |
| 4 yr (SE) | 71 (5) | 80 (5) |